


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on September 14, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1609
Patent Application
Docket No. INN-123
Serial No. 10/537,394

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Michael J. Teale
Art Unit : 1609
Applicants : Francois Romagne, H len  Sicard, J r me Tiollier, Christian Belmant
Serial No. : 10/537,394
Filed : June 2, 2005
Conf. No. : 8478
For : Compositions and Methods for Regulating an Immune Response in a Subject

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR   1.97 AND 1.98


Sir:

In accordance with 37 C.F.R.   1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/537,394
Filing Date	June 2, 2005
First Named Inventor	Francois Romagne
Art Unit	1609
Examiner Name	Michael J. Teale
Attorney Docket Number	INN-123

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-7,109,183	09-19-2006	Belmant <i>et al.</i>	All
	U2	US-7,101,711	09-05-2006	Belmant <i>et al.</i>	All
	U3	US-2006-0030546-A1	02-09-2006	Jomaa <i>et al.</i>	All
	U4	US-2005-0042751-A1	02-24-2005	Goldman <i>et al.</i>	All
	U5	US-2005-0196385-A1	09-08-2005	Romagne <i>et al.</i>	All
	U6	US-2006-0287281-A1	12-21-2006	Belmant <i>et al.</i>	All
	U7	US-2006-0287274-A1	12-21-2006	Belmant <i>et al.</i>	All
	U8	US-2007-0134273-A1	06-14-2007	Romagne <i>et al.</i>	All
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	/Marcos Sznajdman/	Date Considered	04/15/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number	10/537,394
Filing Date	June 2, 2005
First Named Inventor	Francois Romagne
Group Art Unit	1609
Examiner Name	Michael J. Teale
Attorney Docket Number	INN-123

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	VIEWE, E. <i>et al.</i> "Peripheral $\gamma\delta$ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma" <i>Expert Rev. Anticancer Ther.</i> , 2005, pp. 1-14, Vol. 5, No. 6.	
	R2	VIEWE, E. <i>et al.</i> "Phosphostim-Activated $\gamma\delta$ T Cells Kill Autologous Metastatic Renal Cell Carcinoma" <i>The Journal of Immunology</i> , 2005, pp. 1338-1347, Vol. 174.	
	R3	BORDIGNON, C. <i>et al.</i> "Cell therapy: achievements and perspectives" <i>Haematologica</i> , 1999, pp. 1110-1149, Vol. 84.	
	R4	POCCIA, F. <i>et al.</i> "CD94/NGK2 Inhibitory Receptor Complex Modulates Both Anti-Viral and Anti-Tumoral Responses of Polyclonal Phosphoantigen-Reactive V γ 9V δ 2 T Lymphocytes" <i>J. Immunol.</i> , 1997, pp. 6009-6017, Vol. 159.	
	R5	SCIAMMAS, R. <i>et al.</i> "TCR $\gamma\delta$ cells and viruses" <i>Microbes and Infection</i> , 1999, pp. 203-212, Vol. 1.	
	R6	KUNZMANN, Volker <i>et al.</i> "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma" <i>Blood</i> , 2000, pp. 384-392, Vol. 96, No. 2.	
	R7		
	R8		
	R9		
	R10		
	R11		

Examiner Signature	/Marcos Sznajdman/	Date Considered	04/15/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.